

RESEARCH ARTICLE

Proteomic and Transcriptomic Analyses of Swine Pathogen *Erysipelothrix rhusiopathiae* Reveal Virulence Repertoire

Yufeng Li*, Yao Zou, Yuting Xia, Juan Bai, Xianwei Wang, Ping Jiang

Key Laboratory of Bacteriology, Ministry of Agriculture, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China

* yufengli@njau.edu.cn



CrossMark
click for updates

OPEN ACCESS

Citation: Li Y, Zou Y, Xia Y, Bai J, Wang X, Jiang P (2016) Proteomic and Transcriptomic Analyses of Swine Pathogen *Erysipelothrix rhusiopathiae* Reveal Virulence Repertoire. PLoS ONE 11(8): e0159462. doi:10.1371/journal.pone.0159462

Editor: Michael Hensel, University of Osnabrueck, GERMANY

Received: January 25, 2016

Accepted: July 1, 2016

Published: August 1, 2016

Copyright: © 2016 Li et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by public welfare Grants from the Ministry of Agriculture, the People's Republic of China (201203039) and the Priority Academic Program for the Development of Jiangsu Higher Education Institutions (PAPD).

Competing Interests: The authors have declared that no competing interests exist.

Abstract

E. rhusiopathiae is the causative agent of erysipelas in animals and erysipeloid in humans, but its pathogenicity is poorly understood. To identify virulence factors associated with *E. rhusiopathiae* and screen engineered vaccine candidates, we used proteomics and transcriptomics to compare the highly virulent strain HX130709 with an isogenic avirulent derivative, HX130709a. 1,299 proteins and 1,673 transcribed genes were identified and 1,292 of the proteins could be associated with genes. In a comparison between HX130907 and HX130709a, 168 proteins and 475 genes exhibited differences in regulation level. Among these, levels for 61 proteins and transcripts were positively or negatively correlated. Gene Ontology (GO) analysis suggests that many of the down-regulated proteins in the attenuated strain have catalytic or binding functions. Potential protein-protein interactions suggest that some of the down-regulated proteins may regulate PTS, GMP synthase and ribosomal proteins. Morphological results showed that HX130709 and HX130709a have similar colony and capsule morphology. Growth curves and pyruvate measurements suggest that TCA cycle and saccharide phosphorylation levels were decreased and gluconeogenesis was increased in HX130709a. Our study confirms that SpaA and neuraminidase, but not hyaluronidase and capsule, are associated with virulence in *E. rhusiopathiae*. We conclude that the virulence of *E. rhusiopathiae* may be associated with slow reactions of the TCA cycle and down-regulation of selected proteins.

Introduction

Erysipelothrix rhusiopathiae (*E. rhusiopathiae*) is a small gram-positive, slender, and straight rod-shaped bacterium that can cause erysipelas in swine and other animals, including sheep, fish, reptiles and birds. *E. rhusiopathiae* is also an important pathogen in humans and is the causative agent of erysipeloid, a skin disease [1]. The bacterium can be isolated from sick and healthy animals (pork, seafood, chicken) and from environment in which they live [2, 3]. *E. rhusiopathiae* belong to the genus *Erysipelothrix* along with *E. tonsillarum* and two other

unnamed species [4]. Among the 15 serotypes of *E. rhusiopathiae*, serotypes 1a and 2 have the greatest impact on the swine industry [1, 5–9]. Swine erysipelas has caused serious losses in the swine industries of North America, Europe, Asia, and Australia. Swine erysipelas occurs in three forms: acute, subacute, and chronic. The characteristics of acute erysipelas in swine are sudden death or general signs of septicemia. Sub-acute erysipelas causes urticarial or diamond-skin lesions that appear as early as the second or third day after infection. The chronic form of infection can develop from acute or subacute disease, and can be characterized by localized arthritis or proliferative pathological changes in the heart (endocarditis) [10].

E. rhusiopathiae infection in humans is mostly occupationally related, those most prone include butchers, abattoir workers, veterinarians, farmers, fishermen, fish-handlers and housewives [11]. Clinical manifestations in humans are highly similar to those in swine and occur in a localized cutaneous form (erysipeloid), a generalized cutaneous form, and a septicemic form associated with endocarditis [10].

The virulence of *E. rhusiopathiae* varies considerably among different serotypes. Though the mechanisms of pathogenicity are poorly understood, and no toxin has been identified in this organism, several candidate virulence factors have been identified, including neuraminidase [12], capsular antigens [13], RspA and RspB [14], and the 64-66kDa antigen [15]. However, because these studies compared highly virulent with moderate or low virulence strains, the complete virulence repertoire may not have been revealed. In the present study, a highly virulent strain (HX130709) was attenuated by 70 passages on agar medium containing a gradually increasing concentration (0.0025% to 0.03%) of acriflavine dye, with attenuation confirmed by mouse pathogenicity. Proteomic and transcriptomic analyses were then used to identify differences between the attenuated strain HX130709a and its parent, HX130709, to reveal the virulence repertoire of *E. rhusiopathiae*.

Materials and Methods

Reagents

Reagents were obtained from the following sources: 2-D Quant Kit (GE Healthcare), TEAB (Applied Biosystems, Milan Italy), Trypsin Gold (Promega, Madison WI, USA), iTRAQ Reagents -8plex Chemistry (Applied Biosystems), TruSeq SBS KIT-HS, TruSeq PE Cluster Kit and TruSeq SR Cluster Kit (Illumina), TRIzol (Invitrogen), CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega), mouse GAPDH antibody (GeneTex), DNase I (Ambion), Terminator 5'-phosphate-dependent exonuclease (Epicentre).

Bacterial strains and culture conditions

HX130709, a highly virulent strain isolated from a case of septicemia, has been confirmed by PCR and is pathogenic in mice. To generate HX130709a, HX130709 was attenuated by 70 passages on BHI-T80 agar containing an acriflavine dye (0.0025% to 0.03%). The reduced pathogenicity of the attenuated strain was confirmed in mice [16]. Animal experiments were approved by the Institutional Animal Care and Ethics Committee of Nanjing Agricultural University (Approval No. IACECNAU20100902).

Sample preparation

Brain Heart infusion agar and broth supplemented with 0.1% Tween 80 were used for bacterial cultivation. Pure cultures of strains HX130709 and HX130709a were grown in 500 ml of BHI broth for 4 h and 10 h, respectively. Cultures were harvested by centrifugation at 4000 rpm for 15 min at 4°C and washed three times in 1 × PBS buffer. Washed cells were collected in sterile

tubes, flash frozen in liquid nitrogen, and submitted to BGI tech for proteomic and transcriptomic analyses. Three biological replicates were prepared independently for each sample.

Quantitative transcriptomics (RNA-seq)

RNA isolation and mRNA purification. Total RNA was isolated with TRIzol reagent using the standard protocol, and dissolved in 200 μ L RNase-free water. The concentration of total RNA was determined using a NanoDrop spectrophotometer (Thermo Scientific, USA), and the RNA integrity value (RIN) was determined using the RNA 6000 Pico LabChip and an Agilent 2100 Bioanalyzer (Agilent, USA). Total RNA was incubated with 10 U DNase I at 37°C for 1 h, and then nuclease-free water was added to bring the sample volume to 250 μ L. Messenger RNA was further purified by digesting ribosomal RNA and tRNA with Terminator 5'-phosphate-dependent exonuclease. The resulting RNA samples were quantified using a DU800 spectrophotometer (Beckman Coulter, USA) and mixed with fragmentation buffer to generate short mRNA fragments.

cDNA synthesis and Illumina sequencing. cDNA was synthesized using the mRNA fragments as templates. The short cDNA fragments were purified and resuspended in EB buffer for end repair and single nucleotide A (adenine) addition, then ligated to adapters. After agarose gel electrophoresis, appropriately sized products were selected as templates for PCR amplification. During the QC steps, the Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System were used to monitor sample library quantity and quality. The library was sequenced using the Illumina HiSeq™ 2000 high-throughput sequencing system.

Bioinformatics analysis. Sequencing reads were mapped to the reference genome Fujisawa (NC_015601) using BLASTN with a threshold *e* value of 0.00001 and the “-F” parameter [17], which allowed alignments with up to two mismatches. Reads that mapped to rRNA genes or that failed to align using these parameters were excluded from further analysis. The read totals were expressed as RPKM (Reads Per Kilo bases per Million reads) [18] for each gene, and then differently regulated genes were identified using the DEGseq package and the MARS (MA-plot-based method with Random Sampling model) method [19]. We used $FDR \leq 0.001$ and an absolute value of $\log_2\text{Ratio} \geq 1$ as thresholds to judge the significance of differences in gene expression.

Quantitative proteomics

Protein preparation. Harvested bacteria were washed three times with ice-cold phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na_2HPO_4 , 1.8mM KH_2PO_4 , pH 7.4). The supernatant was discarded after the final centrifugation at 12,000 \times g for 30 min. The pellets were extracted with lysis buffer (7 M Urea, 2 M Thiourea, 4% CHAPS, 40 mM Tris-HCl, pH 8.5) with a final concentration of 1mM PMSF and 2mM EDTA. After 5 min of vortexing, DTT was added to the samples to a final concentration of 10 mM. The samples were sonicated at 200 W for 15 min and then centrifuged at 4°C, 30,000 \times g for 15 min. The samples were mixed well with 5 \times volume of ice-cold acetone containing 10% (v/v) TCA and incubated at -20°C overnight. After centrifugation at 4°C, 30,000 \times g, the supernatant was discarded. The precipitate was washed with ice-cold acetone three times. The pellet was vacuum-dried and dissolved in lysis buffer (7M urea, 2 M thiourea, 4% NP40, 20mM Tris-HCl, pH 8.0–8.5). The samples were sonicated at 200 W for 15 min and centrifuged at 4°C, 30,000 \times g for 15 min, and then the supernatant was transferred to a new tube. To reduce disulfide bonds in proteins, 10 mM DTT (final concentration) was added and samples were incubated at 56°C for 1 h. Subsequently, 55 mM IAM (final concentration) was added to block the cysteines, and samples were incubated for 1 h in the dark. The supernatant was mixed well with 5 \times volume of ice-cold

acetone for 2 h at -20°C to precipitate proteins. After centrifugation at 4°C , $30,000 \times g$, the supernatant was discarded and the pellet was vacuum-dried for 5 min. The samples were then dissolved in $500 \mu\text{L}$ 0.5 M TEAB and sonicated at 200 W for 15 min. Finally, samples were pelleted at 4°C , $30,000 \times g$ for 15 min. The supernatant was transferred to a new tube and protein content quantified. Protein preparations were stored at -80°C for later analysis.

iTRAQ (Isobaric tag for relative and absolute quantitation) labeling and SCX fractionation. $100 \mu\text{g}$ of total protein was withdrawn from each sample and then digested at 37°C for 16 hours with Trypsin Gold, at a protein: trypsin ratio of 30: 1. After digestion, peptides were vacuum-dried and re-dissolved in 0.5 M TEAB, then processed with 8-plex iTRAQ reagent, according to the manufacturer's protocol. Briefly, one unit of iTRAQ reagent was thawed and mixed with $24 \mu\text{L}$ isopropanol. The peptides labeled with the isobaric tags were pooled then dried by vacuum centrifugation.

SCX chromatography was performed using a LC-20AB HPLC Pump system (Shimadzu, Kyoto, Japan). The peptide mixtures labeled with isobaric tags were reconstituted in 4 mL buffer A (25 mM NaH_2PO_4 in 25% ACN, pH 2.7) and loaded onto a $4.6 \times 250 \text{ mm}$ Ultremex SCX column containing $5\text{-}\mu\text{m}$ particles (Phenomenex). The peptides were eluted with a gradient of buffer A for 10 min, at a flow rate of $1 \text{ mL}/\text{min}$, then eluted with $5\text{--}60\%$ buffer B (25 mM NaH_2PO_4 , 1 M KCl in 25% ACN, pH 2.7) for 27 min, and then with $60\text{--}100\%$ buffer B for 1 min. Prior to the next sample injection, the system was maintained in 100% buffer B for 1 min, then equilibrated with buffer A for 10 min. Elution was monitored and fractions were pooled every 1 min. The eluted peptides were grouped into 20 fractions and desalted with a Strata X C18 column (Phenomenex) then vacuum-dried.

LC-ESI-MS/MS analysis based on Q EXACTIVE. Each fraction was re-dissolved in buffer A containing 2% ACN and 0.1% FA and centrifuged at $20000 \times g$ for 10 min. The final concentration of peptide was about $0.5 \mu\text{g}/\mu\text{L}$. $10 \mu\text{L}$ supernatant was loaded by autosampler onto a 2 cm C18 trap column for analysis in a LC-20AD nanoHPLC (Shimadzu, Kyoto, Japan). The peptides were eluted onto an analytical C18 column (inner diameter $75 \mu\text{m}$) packed in-house. The samples were loaded at $8 \mu\text{L}/\text{min}$ for 5 min, then the column was run with a gradient from 2% to 35% in buffer B (98% ACN, 0.1% FA) at $300 \text{ nL}/\text{min}$ for 35 min. A linear gradient to 80% was run through the column for 2 min, 80% buffer B was maintained for 4 min then returned to 5% for 1 min.

The peptides subjected to nanoelectrospray ionization were analyzed by tandem mass spectrometry (MS/MS) in a Q EXACTIVE instrument (Thermo Fisher Scientific, San Jose, CA) coupled online with the HPLC. Orbitrap was used to detect intact peptides at a resolution of $70,000$. MS/MS was used to select peptides in high-energy collision dissociation (HCD) operating mode with a normalized collision energy setting of 27.0 and Orbitrap was set at a resolution of $17,500$. The 15 most abundant precursor ions above a threshold ion count of $20,000$ in the MS scan with a subsequent Dynamic Exclusion duration of 15 s were analyzed with a data-dependent procedure that alternated between one MS scan followed by 15 MS/MS scans. The electrospray voltage was set as 1.6 kV . Automatic gain control (AGC) was applied to optimize the spectra generated by the Orbitrap. The AGC target for full MS was 3×10^6 and 1×10^5 for MS2. For MS scans, the m/z scan range was between 350 and $2,000 \text{ Da}$. For MS2 scans, the m/z scan range was between 100 and $1,800$.

Data analysis. Raw data files obtained from the Orbitrap were converted into MGF format using Proteome Discoverer 1.2 (PD 1.2, Thermo), [5600 msconverter]. Proteins were identified using the Mascot search engine (Matrix Science, London, UK; version 2.3.02) against a database (downloaded from NCBI <http://www.ncbi.nlm.nih.gov/protein/?term=txid1648>[Organism:exp]) containing $3,409$ sequences. For protein identification, a mass tolerance of 20 Da (ppm) was used for intact peptide masses and 0.05 Da for fragmented ions, and one missing trypsin cleavage

was permitted in the trypsin digests. Gln->pyro-Glu (N-term Q), Oxidation (M), and Deamidated (NQ) were specified as potential modifications, and Carbamidomethyl (C), iTRAQ8plex (N-term), and iTRAQ8plex (K) were set as invariable modifications. Peptide charge states were set to +2 and +3. We included an automatic decoy database search as part of the analysis. In this option, whenever a protein sequence from the target database is tested, a random decoy sequence of the same length is also tested. To reduce false positives, proteins required support from at least one unique peptide, and only peptides that exceeded “identity” at 99% confidence were accepted.

For protein quantitation, at least two unique peptides were required. The median ratio by Mascot was used to weight and normalize quantitative protein ratios. Proteins with p-values < 0.05 and fold changes > 1.5 were considered to be significantly different between samples.

Functional annotation. The functional annotation of proteins was conducted using the Blast2GO application and the non-redundant (NR) protein database at NCBI. The KEGG database (<http://www.genome.jp/kegg/>) and the COG protein database (<http://www.ncbi.nlm.nih.gov/COG/>) were used to classify and group the identified proteins.

Growth curves

A single colony of HX130709 (F0) and HX130709a (F70) was used to inoculate overnight cultures in BHI medium. 300 μ L overnight culture was inoculated into 30 mL BHI medium and incubated at 200 rpm. 500 μ L samples were collected in triplicate after 1 h and centrifuged at 12,000 rpm for 3 min. The supernatant was discarded, pelleted bacteria were re-suspended in an equal volume of PBS, and optical density (OD_{600 nm}) was measured.

Morphological observations

HX130709 and the attenuated derivative strain HX130709a were streaked onto BHI agar containing 0.1% Tween 80, incubated overnight, and colony morphology observed. Bacteria cultured to log phase were pelleted and fixed with 2.5% glutaraldehyde and then sectioned. Thin sections were stained with uranyl acetate and lead citrate and examined with a Hitachi H-7500 transmission electron microscope.

Lactate dehydrogenase activity

Bacteria were cultured to mid-logarithmic phase in BHI medium at 37°C. Triplicate samples were collected for each of 3 time points for the virulent strain HX130709 (5h, 6h, 7h) and the attenuated strain HX13079a (8h, 9h, 10h). Each 10 mL sample was centrifuged at 6,000 rpm for 10 min, then washed in PBS 3 times. Pelleted bacteria were resuspended in 500 μ L PBS and lysed by sonication. The lysate was centrifuged at 12,000 rpm for 1 min and supernatant collected. 50 μ L supernatant was added to wells in 96-well plates, lactate dehydrogenase (LDH) substrate was added, and the plates were incubated at 37°C for 30 min, following the protocol accompanying the CytoTox 96 Non-Radioactive Cytotoxicity Assay kit. Color development was halted by the addition of stop solution and optical density at 490 nm (OD₄₉₀) was recorded using an ELISA plate reader (BioTek, USA). In parallel, sampled bacteria were plated at a final dilution of 10⁻⁷ on BHI agar plates to determine bacterial concentration (colony forming units, CFU). Results were expressed as LDH/cfu.

Results and Discussion

Summary of RNA-seq and iTRAQ data

Transcriptome data were obtained by high-throughput RNA-sequencing as described in materials and methods. Three RNA samples were analyzed from HX130709 and its attenuated

derivative HX130709a (six samples total). After excluding low-scoring sequence reads, the average read length was 90 bp and the total reads obtained were 3,675,074, 4,692,139 and 3,839,099 for samples HX130709-1, -2, -3 respectively, and 3,251,469, 4,755,689 and 5,151,752 for samples HX130709a-1, -2, -3, respectively. Correlation analysis among the replicates of HX130709, and among the replicates of HX130709a, generated Pearson's correlation coefficients over 0.95 except in two cases. Because the coefficients for HX130709a-1 vs. HX130709a-2 (0.206) and HX130709a-1 vs. HX130709a-3 (0.2008) were unacceptably low, the HX130709a-1 data set was discarded. In spite of this loss, the mean sequencing coverage for both strains was 193–259 fold. Reads were mapped to the *E. rhusiopathiae* genome sequence (Fujisawa) using Soap (v2.01). The results indicated that the transcriptional percentages for ORFs encoded by the Fujisawa strain were 96.37% and 84.58% for HX130709 and HX130709a, respectively. Surprisingly, no SNPs were found in HX130709 or HX130709a. Gene differential regulation was analyzed using the DEGseq software package. Out of 1,673 genes examined, 197 genes exhibited increased transcription in HX130709a and 278 genes exhibited decreased transcription, relative to the levels in HX130709 (S1 Table).

Three biological replicates for each strain were included in the iTRAQ experiment comparing virulent HX130709 and avirulent HX130709a. After trypsinization and labeling with distinct isobaric tags, protein fragments in the six samples were separated and identified by LC-ESI-MS/MS. Because the error distribution analysis among the replicates of HX130709, and among the replicates of HX130709a, showed that the mean errors for HX130709a-1 with replicas -2 and -3 were 1.37 and 1.43, respectively, the data obtained from HX130709a-1 was again set aside. In the five remaining samples, a total of 312,350 mass spectra were generated. After excluding low-scoring spectra, 79,681 unique spectra that matched to specific peptides were obtained. Mascot analysis identified 12,154 peptides, 11,655 unique peptides, and 1,299 proteins in total, in the five samples (S1 File). Covariance distribution analysis for these samples yielded a mean covariance of 0.063 (S1 Fig), indicating good reproducibility between biological replicates in each group. A protein with ≥ 1.5 -fold difference and p -value ≤ 0.05 was regarded as being differentially regulated. Relative to protein levels in the virulent strain HX130709, the abundance of 101 proteins increased, and 67 proteins decreased, in HX130709a (Table 1).

Functional annotation of the 1299 proteins was based on the three principal classifications developed by the gene ontology (<http://www.geneontology.org>). With respect to biological processes, most proteins were associated with metabolic processes (32.18%) and cellular processes (26.68%). When classified according to cellular component, 30.76% of proteins were described as located in the cell, 30.76% in cell parts, 13.14% in membranes, and 9.45% in membrane parts. Classification by molecular function showed that most proteins had catalytic (46.97%) and binding (36.54%) activities (Fig 1). Overall, the gene ontology classifications for the differentially expressed proteins are very similar to those obtained for all 1,299 proteins identified by Mascot. However, when the differentially expressed proteins are classified by molecular function, catalytic activity (50.75% vs. 44.07%) and binding (34.33% vs. 29.66%) are overrepresented.

The COG database (<http://www.ncbi.nlm.nih.gov/COG>) was used to classify and group the identified proteins (Fig 2). The ten most common categories were as follows: [R] General function prediction (~13.93%), [J] Translation, ribosomal structure and biogenesis (~11.08%), [K] Transcription (~10.31%), [G] Carbohydrate transport and metabolism (~8.39%), [M] Cell wall/membrane/envelope biogenesis (~7.00%), [L] Replication, recombination and repair (~6.85%), [S] Function unknown (~6.39%), [E] Amino acid transport and metabolism (~6.31%), [P] Inorganic ion transport and metabolism (~5.77%), and [T] Signal transduction mechanisms (~4.77%). As expected, the majority of proteins are involved in basic cellular functions, such as replication, transcription, translation and metabolism.

Table 1. Differentially regulated proteins identified in proteome and transcriptome (HX130709a/HX130709). Protein level differences with p-values < 0.05, and fold changes of >1.5 were considered significant.

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
Up-regulation proteins (101)							
gi 336065729	hypothetical protein	33	6	2.005	Unknown		
gi 322464469	polysaccharide deacetylase	57.2	23	1.563	Predicted xylanase/chitin deacetylase		
gi 322462985	LytTr DNA-binding domain protein	35.9	4	1.502	Response regulator of the LytR/AlgR family		
gi 336065511	two-component system response regulator	62.2	13	1.949	Response regulator of the LytR/AlgR family	up	ERH_0269
gi 322463071	amino acid permease	2.1	1	1.606	Amino acid transporters	up	ERH_0305
gi 336066470	hypothetical protein	74.3	4	1.718	Unknown	down	ERH_1233
gi 336065272	ferric uptake regulator family protein	58.3	7	1.56	Fe2+/Zn2+ uptake regulation proteins		
gi 322463447	ABC transporter, substrate-binding protein, QAT family	44.1	10	6.58	Periplasmic glycine betaine/choline-binding (lipo)protein of an ABC-type transport system (osmoprotectant binding protein)	up	ERH_1627
gi 336065597	glutaredoxin-like protein NrdH	75	5	2.394	Thiol-disulfide isomerase and thioredoxins	down	ERH_0356
gi 336066593	peptidase, M23B family	3.2	2	1.565	Membrane proteins related to metalloendopeptidases		
gi 336066734	spermidine/putrescine ABC transporter ATP-binding protein	70.3	16	2.416	ABC-type spermidine/putrescine transport systems, ATPase components	up	ERH_1498
gi 336066419	hypothetical protein	7.1	2	1.666	Unknown		
gi 322464148	hypothetical protein HMPREF0357_10136	17.5	5	1.512	Predicted nucleotidyltransferase		
gi 336066664	LPXTG-motif cell wall anchor domain-containing protein	9	13	1.535	Unknown		
gi 489869940	signal peptidase	37.9	2	2.437	Unknown	down	ERH_0786
gi 489872223	PTS cellobiose transporter subunit IIC	6.8	3	6.19	Phosphotransferase system cellobiose-specific component IIC	up	ERH_0219
gi 322464339	biotin/lipoate A/B protein ligase family protein	40.9	7	1.554	Lipoate-protein ligase A	down	ERH_0787
gi 322464475	helix-turn-helix protein, YixM/p13 family	27.8	3	1.646	Uncharacterized protein conserved in bacteria		
gi 322463067	response regulator receiver domain protein	32.5	6	1.514	Response regulators consisting of a CheY-like receiver domain and a winged-helix DNA-binding domain		
gi 489869961	carbamate kinase	30.9	7	1.809	Carbamate kinase	down	ERH_0797
gi 336066177	ABC transporter ATP-binding protein	49.2	8	1.662	ABC-type multidrug transport system, ATPase component	up	ERH_0939
gi 336066253	formamidopyrimidine-DNA glycosylase	23.4	4	1.916	Formamidopyrimidine-DNA glycosylase		
gi 336066573	copper chaperone	71.4	4	1.805	Unknown		
gi 336065993	oxaloacetate decarboxylase subunit alpha	38.5	13	4.116	Pyruvate/oxaloacetate carboxyltransferase		
gi 336066878	hypothetical protein	13.6	1	2.808	Unknown		
gi 336066225	hypothetical protein	8.5	2	1.665	ABC-type uncharacterized transport system, permease component		
gi 489870987	thioredoxin	69.6	5	1.964	Thiol-disulfide isomerase and thioredoxins	down	ERH_1500
gi 322463512	hypothetical protein HMPREF0357_10813	52.4	5	1.99	Unknown		
gi 336065984	triphosphoribosyl-dephospho-CoA synthase	19.6	4	2.114	Triphosphoribosyl-dephospho-CoA synthetase	up	ERH_0746

(Continued)

Table 1. (Continued)

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
gi 322464227	CAAX amino terminal protease family protein	6.2	2	1.789	Predicted metal-dependent membrane protease		
gi 336066870	hypothetical protein	36.1	4	2.983	Unknown		
gi 336066016	hypothetical protein	57.3	7	2.395	Uncharacterized conserved protein		
gi 322463205	glycerophosphodiester phosphodiesterase family protein	18.6	10	1.705	Glycerophosphoryl diester phosphodiesterase		
gi 336066010	prolyl aminopeptidase	30	7	1.914	Predicted hydrolases or acyltransferases (alpha/beta hydrolase superfamily)	up	ERH_0772
gi 322463949	hypothetical protein HMPREF0357_11250	57.6	6	1.981	Predicted DNA-binding protein with PD1-like DNA-binding motif		
gi 336066178	hypothetical protein	9.7	5	1.987	Unknown		
gi 336066448	TetR family transcriptional regulator	34.8	6	1.53	Transcriptional regulator		
gi 336065561	Crp/Fnr family transcriptional regulator	12.1	2	2.196	Predicted transcriptional regulators		
gi 336065842	hypothetical protein	40	2	2.474	Unknown	down	ERH_0602
gi 336065758	tyrosine recombinase XerC	35.1	8	1.617	Site-specific recombinase XerD		
gi 336065996	oxaloacetate decarboxylase subunit beta	10.8	4	2.757	Na ⁺ -transporting methylmalonyl-CoA/oxaloacetate decarboxylase, beta subunit		
gi 336065500	endonuclease/exonuclease/phosphatase family protein	11	3	1.852	Unknown		
gi 489872418	methionine sulfoxide reductase A	55.2	5	1.982	Peptide methionine sulfoxide reductase		
gi 336066213	putative metalloprotease	25.9	3	1.62	Predicted metal-dependent hydrolase		
gi 489871071	peptide ABC transporter ATP-binding protein	16.8	4	2.263	ABC-type antimicrobial peptide transport system, ATPase component		
gi 336065450	D-alanine—poly(phosphoribitol) ligase subunit 2	31.6	2	1.769	Unknown	down	ERH_0208
gi 489871733	ABC transporter	11.6	1	4.118	ATPase components of ABC transporters with duplicated ATPase domains		
gi 322463931	BadF/BadG/BcrA/BcrD ATPase family protein	31.6	7	1.671	Predicted N-acetylglucosamine kinase		
gi 336065340	acid phosphatase/vanadium-dependent haloperoxidase related protein	18.2	2	1.864	Uncharacterized protein conserved in bacteria	up	ERH_0098
gi 322463944	acetyltransferase, GNAT family	30.6	4	1.693	Histone acetyltransferase HPA2 and related acetyltransferases		
gi 336066251	replication initiation and membrane attachment protein	35.8	13	1.775	Replication initiation/membrane attachment protein		
gi 322463437	HD domain protein	24.4	8	1.55	HD superfamily phosphohydrolases		
gi 336066440	hypothetical protein	67.2	6	1.878	Unknown	down	ERH_1203
gi 336065559	N-acetyltransferase GCN5	14.6	2	1.858	Acetyltransferases, including N-acetylases of ribosomal proteins		
gi 336066518	hypothetical protein	10.3	1	2.093	Unknown	down	ERH_1282
gi 489869871	citrate lyase	34	5	1.838	Phosphoribosyl-dephospho-CoA transferase (holo-ACP synthetase)		
gi 336065544	YeeE/YedE family integral membrane protein	21.4	8	1.68	Predicted transporter component	up	ERH_0303
gi 336065463	glycoside hydrolase	23.6	11	4.251	Beta-glucanase/Beta-glucan synthetase	up	ERH_0221
gi 336065828	hypothetical protein	34.1	3	1.767	Unknown	down	ERH_0588
gi 489869873	citrate lyase subunit gamma	27.6	2	3.173	Citrate lyase, gamma subunit		
gi 336066517	copper chaperone	17.3	1	2.156	Copper chaperone		

(Continued)

Table 1. (Continued)

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
gi 322463327	ABC 3 transport family protein	10.3	4	2.911	ABC-type Mn ²⁺ /Zn ²⁺ transport systems, permease components		
gi 336065783	MarR family transcriptional regulator	17.7	2	2.505	Unknown		
gi 336065994	putative oxaloacetate decarboxylase subunit gamma	18	1	3.612	Transcriptional regulators		
gi 322463480	transcriptional regulator, LysR family	16.8	4	1.506	Unknown		
gi 29603463	rhusiopathiae surface protein B	4.7	3	3.364	Transcriptional regulator		
gi 336065820	host cell surface-exposed lipoprotein	17.6	2	1.502	Unknown		
gi 336066586	D-methionine ABC transporter ATP-binding protein	61.8	3	2.205	Unknown		
gi 336065271	hypothetical protein	51	2	1.635	ABC-type metal ion transport system, ATPase component	up	ERH_0029
gi 322463387	LPXTG-motif cell wall anchor domain protein	16.6	1	2.225	Uncharacterized conserved protein	up	ERH_1687
gi 322463680	ABC transporter, permease protein	2.3	1	17.319	Unknown	down	ERH_1245
gi 336066678	glycosyltransferase family protein	32.8	11	1.543	ABC-type sugar transport systems, permease components	down	ERH_1442
gi 336065843	hypothetical protein (Glycosyltransferases)	15.4	2	1.706	Glycosyltransferases involved in cell wall biogenesis		
gi 336066252	dephospho-CoA kinase	25.6	4	2.513	Predicted membrane protein		
gi 322464309	Biotin-requiring enzyme	19.6	2	6.095	Dephospho-CoA kinase	up	ERH_0757
gi 322463815	LPXTG-motif cell wall anchor domain protein	13.5	11	2.184	Biotin carboxyl carrier protein		
gi 336065715	hypothetical protein	18.1	5	1.712	Unknown	up	ERH_0475
gi 322464470	ATPase/histidine kinase/DNA gyrase B/HSP90 domain protein	35.2	12	2.296	Predicted periplasmic solute-binding protein		
gi 322464365	hypothetical protein HMPREF0357_10353	5.8	1	3.662	Signal transduction histidine kinase		
gi 322463326	ABC 3 transport family protein	8.3	3	2.436	Unknown	down	ERH_0047
gi 336066379	XRE family transcriptional regulator	54.4	3	2.366	ABC-type Mn ²⁺ /Zn ²⁺ transport systems, permease components		
gi 509078903	ABC transporter, permease protein	6.6	2	1.617	Predicted transcriptional regulators	down	ERH_1244
gi 336066105	ACT domain-containing protein	30.3	3	1.705	ABC-type sugar transport system, permease component	up	ERH_0867
gi 322464145	putative endoribonuclease L-PSP	27.1	3	1.806	ACT domain-containing protein		
gi 336065349	DNA binding helix-turn helix protein	52.9	4	1.579	Putative translation initiation inhibitor, yjgF family		
gi 336066891	MutT/NUDIX family protein	48.6	7	3.258	Predicted transcriptional regulator		
gi 336066864	glycine betaine/carnitine/choline ABC transporter permease	21.1	3	8.34	NTP pyrophosphohydrolases including oxidative damage repair enzymes	up	ERH_1629
gi 322463363	DNA replication and repair protein RecF	9.4	3	1.701	ABC-type proline/glycine betaine transport systems, permease component	up	ERH_0007
gi 336066579	purine nucleosidase	50.5	13	1.543	Recombinational DNA repair ATPase (RecF pathway)		
gi 336066735	XRE family transcriptional regulator	42.9	5	2.366	Inosine-uridine nucleoside N-ribohydrolase		

(Continued)

Table 1. (Continued)

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
gi 336066556	N-acetyltransferase GCN5	2.1	1	1.665	Predicted transcriptional regulators		
gi 489871234	PTS glucose transporter subunit IIBC	15.3	5	2.049	Acetyltransferases, including N-acetylases of ribosomal proteins	down	ERH_1399
gi 336065655	ABC transporter permease	6.1	2	1.522	Phosphotransferase system IIC components, glucose/maltose/N-acetylglucosamine-specific	up	ERH_0414
gi 336065992	citrate-sodium symporter	9.7	4	2.961	ABC-type sugar transport systems, permease components		
gi 336065983	GntR family transcriptional regulator	37.6	8	1.991	Na+/citrate symporter		
gi 336066469	hypothetical protein	16.9	2	1.753	Transcriptional regulators		
gi 336066654	MutT/NUDIX family protein	8.8	1	1.759	Unknown		
gi 336065454	two-component system sensor histidine kinase	25.8	8	2.469	ADP-ribose pyrophosphatase		
gi 336066363	ABC transporter ATP-binding protein	19.7	3	1.696	Signal transduction histidine kinase		
gi 489870514	beta-carotene 15,15--monooxygenase	12.3	3	1.533	ATPase components of ABC transporters with duplicated ATPase domains	up	ERH_0064
gi 336066325	hypothetical protein ERH_1087	16.8	3	1.858	Uncharacterized conserved protein	up	ERH_1087
Down-regulation proteins (67)							
gi 336066742	hypothetical protein	25.5	4	0.52	Unknown		
gi 336066589	aspartate—ammonia ligase	32.6	9	0.407	Asparagine synthetase A	down	ERH_1353
gi 336066753	amino acid ABC transporter amino acid-binding protein	17.9	4	0.294	ABC-type amino acid transport/signal transduction systems, periplasmic component/domain	down	ERH_1517
gi 336065791	methionine adenosyltransferase	50.8	15	0.553	S-adenosylmethionine synthetase		
gi 336065393	putative D-alanyl-D-alanine carboxypeptidase	13.1	5	0.552	D-alanyl-D-alanine carboxypeptidase		
gi 489869850	bacteriocin ABC transporter ATP-binding protein	33.8	4	0.55	ABC-type antimicrobial peptide transport system, ATPase component		
gi 336066913	hypothetical protein	24.9	18	0.277	Unknown	down	ERH_1678
gi 322463568	cell envelope-like function transcriptional attenuator common domain protein	14.3	7	0.617	Transcriptional regulator		
gi 336065737	putative SUF system FeS cluster assembly protein SufD	37.9	8	0.637	ABC-type transport system involved in Fe-S cluster assembly, permease component		
gi 322463946	putative Na/Pi-cotransporter II-like protein	21.6	10	0.584	Na+/phosphate symporter		
gi 105303396	surface protective antigen SpaA	41.5	1	0.248	FOG: Glucan-binding domain (YG repeat)	down	ERH_0094
gi 336065502	subtilase family cell-envelope associated proteinase	4.5	4	0.503	Subtilisin-like serine proteases		
gi 336065501	cold-shock protein	74.2	4	0.503	Cold shock proteins		
gi 336065445	Na+ efflux pump ABC transporter permease	27	10	0.245	ABC-type Na+ efflux pump, permease component	down	ERH_0203
gi 336066925	guanosine monophosphate reductase 2	58.3	16	0.558	IMP dehydrogenase/GMP reductase	down	ERH_1690
gi 336065366	type III pantothenate kinase	22.3	4	0.571	Putative transcriptional regulator, homolog of Bvg accessory factor	down	ERH_0124
gi 336066690	LPXTG-motif cell wall anchor domain-containing protein	27.7	6	0.179	Unknown	down	ERH_1454
gi 336065396	hypothetical protein	54.7	19	0.196	Unknown	down	ERH_0154

(Continued)

Table 1. (Continued)

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
gi 18146962	Tet(M)	44.6	21	0.246	Translation elongation factors (GTPases)		
gi 322463820	hypothetical protein HMPREF0357_11121	15.6	4	0.485	Unknown	down	ERH_1253
gi 489869985	hypothetical protein	8.3	1	0.493	Unknown	down	ERH_0811
gi 322463107	transcriptional regulator, TetR family	24.7	4	0.581	Unknown		
gi 489871386	dipeptidase	58.5	9	0.339	Peptidase E	down	ERH_1312
gi 322464532	response regulator receiver domain protein	24.6	5	0.444	Response regulators consisting of a CheY-like receiver domain and a winged-helix DNA-binding domain	down	ERH_0982
gi 336066596	ABC transporter permease	34.2	12	0.54	ABC-type antimicrobial peptide transport system, permease component		
gi 336065388	inositol monophosphatase family protein	45.5	9	0.159	Archaeal fructose-1,6-bisphosphatase and related enzymes of inositol monophosphatase family		
gi 336066608	ABC transporter ATP-binding protein	35.2	6	0.508	ABC-type multidrug transport system, ATPase component		
gi 336066551	peptidase, M42 family	46.4	11	0.536	Cellulase M and related proteins	down	ERH_1315
gi 489871941	pyrrolidone-carboxylate peptidase	59.2	11	0.393	Pyrrolidone-carboxylate peptidase (N-terminal pyroglutamyl peptidase)	down	ERH_0382
gi 336066606	enterochelin ABC transporter substrate-binding protein	39.1	9	0.48	ABC-type enterochelin transport system, periplasmic component		
gi 336066243	basic membrane lipoprotein	42.1	10	0.558	Uncharacterized ABC-type transport system, periplasmic component/surface lipoprotein		
gi 336065553	two-component system response regulator	34.2	6	0.537	Response regulators consisting of a CheY-like receiver domain and a winged-helix DNA-binding domain		
gi 336065967	leucine-rich repeat protein	13.5	5	0.64	Leucine-rich repeat (LRR) protein	down	ERH_0728
gi 322463725	PASTA domain protein	31.8	13	0.51	Unknown	down	ERH_1362
gi 322463102	hypothetical protein HMPREF0357_11450	7.8	1	0.531	Unknown		
gi 503619403	hypothetical protein	37.4	4	0.629	Unknown		
gi 336066550	hypothetical protein	30.6	3	0.602	Unknown		
gi 336066068	CobQ/CobB/MinD/ParA nucleotide binding domain-containing protein	26.9	8	0.402	Flp pilus assembly protein, ATPase CpaE		
gi 336066221	phosphate starvation-inducible protein PhoH	64.2	14	0.238	Phosphate starvation-inducible protein PhoH, predicted ATPase	down	ERH_0983
gi 322463351	PTS system glucoside-specific EIICBA component family protein	23	9	0.666	Phosphotransferase system IIC components, glucose/maltose/N-acetylglucosamine-specific		
gi 489872217	PTS glucose transporter subunit IABC	15.7	6	0.208	Phosphotransferase system IIC components, glucose/maltose/N-acetylglucosamine-specific	down	ERH_0222
gi 336065624	hypothetical protein	8.8	2	0.467	Predicted membrane protein	down	ERH_0383
gi 336066461	2-dehydro-3-deoxygluconokinase	28.5	9	0.653	Sugar kinases, ribokinase family		
gi 322464377	Flp/Fap pilin component	14.3	1	0.304	Flp pilus assembly protein, pilin Flp	down	ERH_0825
gi 489869981	ABC transporter ATP-binding protein	47.4	7	0.186	ABC-type multidrug transport system, ATPase component	down	ERH_0807
gi 336066791	peptide chain release factor 2	40.9	11	0.634	Protein chain release factor B		
gi 336065318	N-acetyltransferase GCN5	22.8	5	0.642	Histone acetyltransferase HPA2 and related acetyltransferases		

(Continued)

Table 1. (Continued)

Accession	Description	Cov	Unique Peptide	ratio	functions	mRNA expression	Gene ID
gi 336066001	hypothetical protein	30	4	0.658	FOG: CBS domain		
gi 489872308	flavin reductase	37.2	5	0.628	Predicted flavoprotein		
gi 489871309	multidrug ABC transporter ATP-binding protein	25.2	6	0.593	ABC-type antimicrobial peptide transport system, ATPase component	down	ERH_1361
gi 489871187	ABC transporter	40.7	17	0.57	ABC-type multidrug transport system, ATPase and permease components		
gi 489872323	inositol monophosphatase	48.6	11	0.599	Archaeal fructose-1,6-bisphosphatase and related enzymes of inositol monophosphatase family		
gi 336066429	DNA polymerase IV	12.1	3	0.645	Nucleotidyltransferase/DNA polymerase involved in DNA repair		
gi 322464283	hypothetical protein HMPREF0357_10271	6.4	1	0.555	Unknown	down	ERH_0732
gi 322463718	ABC transporter, ATP-binding protein	3.5	1	0.497	ABC-type enterochelin transport system, ATPase component		
gi 322463306	hypothetical protein HMPREF0357_10606	5.1	1	0.649	Unknown		
gi 322464381	Flp pilus assembly protein CpaB	35.3	7	0.327	Flp pilus assembly protein CpaB		
gi 489870985	diacylglycerol kinase	27.1	7	0.655	Sphingosine kinase and enzymes related to eukaryotic diacylglycerol kinase		
gi 336065298	sulfatase family protein	31.7	15	0.446	Phosphoglycerol transferase and related proteins, alkaline phosphatase superfamily		
gi 336066345	alpha/beta hydrolase domain-containing protein	18.7	4	0.326	Esterase/lipase		
gi 322464343	ABC transporter, ATP-binding protein	11.2	6	0.659	ABC-type transport system involved in cytochrome bd biosynthesis, ATPase and permease components		
gi 336066648	ABC transporter permease/ATP-binding protein	23.6	14	0.644	ABC-type multidrug transport system, ATPase and permease components		
gi 322463081	NMT1/THI5-like protein	37.7	1	0.485	ABC-type nitrate/sulfonate/bicarbonate transport systems, periplasmic components		
gi 336065736	Fe-S cluster assembly ATP-binding protein	62	15	0.533	ABC-type transport system involved in Fe-S cluster assembly, ATPase component		
gi 336066238	peptidase M16 domain-containing protein	44.9	7	0.577	Predicted Zn-dependent peptidases		
gi 489871578	PTS sugar transporter	71.5	6	0.409	Phosphotransferase system, mannose/fructose-specific component IIA		
gi 336065707	hemolysin-like protein	28.7	10	0.396	Hemolysins and related proteins containing CBS domains		

doi:10.1371/journal.pone.0159462.t001

Correlation between mRNA and protein expression profiles

A coupled transcriptomics-proteomics project provides a unique opportunity to investigate whether protein regulation is correlated with gene transcription. We investigated the correlation between mRNA and protein profiles and found that the levels of 1219 proteins could be correlated, either negatively or positively, with mRNA levels. Among the 168 differentially regulated proteins, only 61 could be correlated with mRNA level variations. These proteins could be clustered into four groups based on the pattern of changes in mRNA and protein levels: Group I, the mRNA and protein levels are positively correlated (45 proteins); Group II, the mRNA level remains almost unchanged while the protein level is decreased (43 proteins);




Fig 1. Protein classification based on functional annotations using the Gene Ontology resource. (A) GO biological processes; (B) GO molecular functions; and (C) GO cellular components. p-values were calculated using tools at the Life Science Website.

doi:10.1371/journal.pone.0159462.g001

Group III, the mRNA level remains almost unchanged but the protein level is increased (64 proteins); Group IV, the mRNA level is decreased but the protein level is increased (16 proteins) (Table 1). Group I includes two subgroups: both the mRNA and protein levels are increased synchronously (21 proteins); both the mRNA and protein levels are decreased synchronously (24 proteins) (Table 1).

Protein-protein interaction analysis

Protein-protein interactions play an important role in bacterial pathogenicity and metabolism. We therefore examined the 67 down-regulated proteins for potential protein interactions using the STRING database [20]. Associations were predicted to exist among these proteins, and




Fig 2. Classification of protein functions based on COGs.

doi:10.1371/journal.pone.0159462.g002




Fig 3. Potential protein–protein interaction network among down-regulated proteins as analyzed by STRING. Stronger associations are represented by thicker lines. Red dots indicate predicted proteins that have strong associations with the down-regulated proteins.

doi:10.1371/journal.pone.0159462.g003

especially between them and components of the phosphotransferase system, GMP synthases and ribosomal proteins (Fig 3). These interactions may function in reducing nucleotide and protein synthesis and saccharide phosphorylation.

Phosphotransferase system (PTS)

The phosphoenolpyruvate sugar phosphotransferase system (PTS) is widespread among micro-organisms. The PTS couples carbon source uptake and substrate phosphorylation, generating intracellular sugar-phosphate [21]. Pathway analysis suggests that the phosphorylation levels of glucose, maltose, D-glucosamine, N-acetylgalactosamine and galactosamine were down-regulated (1.6–5 fold) in HX130709a, resulting in reduced glucose 6-phosphate and glyceralde-hydes-3-phosphate synthesis, consistent with the up-regulation of gluconeogenesis (Fig 4).




Fig 4. Pathway analysis of up- and down-regulated proteins associated with the TCA cycle.

doi:10.1371/journal.pone.0159462.g004





Fig 5. Growth curves for HX130709 and its attenuated derivative HX130907a. HX130709 and HX130709a were cultured and triplicate samples were collected at 1 h intervals. The samples were centrifuged and pellets suspended in an equal volume of PBS. Values shown are optical densities (600 nm).

doi:10.1371/journal.pone.0159462.g005

TCA Cycle

A pathway analysis focused on the TCA cycle showed that the pathway components responsible for the conversion of pyruvate and citrate to oxaloacetate were up-regulated in HX130709a relative to HX130709. In contrast, components involved in the metabolism of succinate to fumarate were down-regulated. We hypothesize that the lower levels of medium-supplied carbohydrates were used by the attenuated *E. rhusiopathiae*, but the cells compensated by up-regulating production of oxaloacetate and shunting excess oxaloacetate into the gluconeogenesis pathway. However, pathway components involved in the conversion of pyruvate to acetyl-CoA were not changed. Combining this fact with the down-regulation of components involved in the metabolism of succinate to fumarate, we suggest that the TCA cycle as a whole is down-regulated in HX130709a (Fig 4). Growth curves also showed that HX130709 grows more rapidly than HX130709a (Fig 5). Compared with HX130709, pyruvate levels in HX130709a may be slightly higher, but the difference is not significant (Fig 6). The colony morphology of HX130709a was convex and irregular, similar to that of HX130709. Electron microscopy



Strain	LDH			Colony forming unit (CFU)			Average	LDH/CFU(10 ⁻¹⁰)		
	0.266	0.224	0.237	Average	86	74			109	
HX130709	5h	0.266	0.224	0.237	0.242	86	74	109	89.667	1.351
	6h	0.422	0.499	0.515	0.479	213	270	290	257.667	0.929
	7h	0.451	0.498	0.326	0.425	279	301	312	297.333	0.715
HX130709a	8h	0.199	0.2	0.222	0.207	139	61	83	94.333	1.097
	9h	0.391	0.321	0.372	0.361	142	107	198	149	1.212
	10h	0.318	0.351	0.361	0.343	178	183	180	180.333	0.952

Fig 6. Pyruvate detection with LDH assay. Bacteria were cultured to mid-logarithmic phase in BHI medium and triplicate samples were collected at 3 time points for the virulent strain HX130709 (5 h, 6 h, 7 h) and the attenuated strain HX13079a (8 h, 9 h, 10 h). Lactate dehydrogenase levels and bacterial counts (colony forming units; CFU) were measured as described in materials and methods. Results are expressed as LDH/cfu. Pyruvate levels are assumed to correlate positively with LDH activity.

doi:10.1371/journal.pone.0159462.g006




Fig 7. Morphological observation of HX130709 and HX130709a. Colony morphology and electron micrographs of *E. rhusiopathiae*. Colony morphology of (A) HX130709 and (B) HX130709a. Electron micrographs of (C) HX130709 and (D) HX130709a. The scale bar is 100 nm.

doi:10.1371/journal.pone.0159462.g007

showed capsule material as an electron-dense layer outside the outer membrane and no significant morphological difference between the virulent and attenuated strains (Fig 7), which is inconsistent with the result reported by Yoshihiro et al. [13, 22]. The role of the capsule in virulence has been clearly demonstrated using isogenic mutants with defined mutations. However, differences in growth curves and pyruvate metabolism between parent strains and their avirulent derivatives have not been reported, nor have differences in mRNA and protein levels. Our results demonstrate that capsule is not closely associated with virulence in *E. rhusiopathiae*.

Virulence factors

In a previous study, Kwok and Li sequenced the genome of a virulent strain of *E. rhusiopathiae* (SY1027) and used BLASTP and VFDB to identify 37 potential virulence factors [23]. Using a similar strategy, we examined the proteins and genes identified by proteomic and transcriptomic analyses in our study and found 13 virulence factor candidates. To our surprise, compared with HX130709, no potential virulence factors were differentially expressed in HX130709a. However, it is possible that these factors are not associated with pathogenicity in *E. rhusiopathiae*.

Virulence factors such as neuraminidase, hyaluronidase, RspA/RspB, SpaA, and hemolysin have been suggested to play a role in *E. rhusiopathiae* pathogenicity. Among the proteins and genes identified in our transcriptomic and proteomic analyses, transcriptional activity was detected for neuraminidase, hyaluronidase and *spaA*, which were decreased 2.7, 2.35 and 15.8 fold in HX130709a vs. HX130709, respectively. Unexpectedly, neuraminidase was not detected as a protein product, nor were transcripts detected that corresponded to the *rspA/rspB* genes. Since pelleted bacteria were used in the proteomic and transcriptomic analyses, it is possible that neuraminidase was secreted into the culture medium and that the mRNAs for *rspA/rspB* were unstable. Protein levels for hyaluronidase and RspA were stable, but protein levels for

RspB and SpaA were increased and decreased 3.364 and 4 fold, respectively. Hemolysin was not detected in mRNA or protein forms, but a hemolysin-like protein was identified and its protein level was down-regulated.

Neuraminidase is an enzyme responsible for cleavage of sialic acids from sialo-glycoconjugates such as glycoproteins, glycolipids, and oligo- and polysaccharides. The down-regulation of neuraminidase has been associated with decreased virulence in *E. rhusiopathiae* [10]. We found that the mRNA level of neuraminidase was decreased 2.7 fold in attenuated strain HX130907a, which is consistent with this result. Shimoji et al. conducted transposon mutagenesis with Tn916 to construct mutants defective in hyaluronidase production and reported that hyaluronidase was not associated with virulence in *E. rhusiopathiae* [24]. Although mRNA levels for hyaluronidase decreased 2.35 fold in our study, protein expression were essentially identical in HX130709 and HX130907a, providing additional support that hyaluronidase is not associated with virulence in *E. rhusiopathiae*. RspA expression was also identical in the two strains, but RspB was increased in the attenuated strain HX130907a, suggesting that RspA and RspB are not associated with virulence in *E. rhusiopathiae*. Finally, Borrathybay et al. deleted the *spaA* gene from wild-type *E. rhusiopathiae* strain C43065 and found that the virulence of the $\Delta spaA$ mutant decreased more than 76 fold [25], but they did not compare growth curves for the wild-type and mutant strains. We also found that *spaA* transcription and SpaA protein levels decreased in HX130907a, supporting the hypothesis that SpaA is associated with virulence in *E. rhusiopathiae*.

In summary, the transcriptomes and proteomes of an attenuated *E. rhusiopathiae* and its parent strain were compared. 475 genes and 168 proteins were found to be up- or down-regulated and the levels for 61 proteins could be correlated with gene transcription levels. The growth of the attenuated strain is slower than its parent strain, but pyruvate metabolism appears to be unaffected. Our data are consistent with other studies showing that SpaA and neuraminidase, but not hyaluronidase and capsule, are associated with virulence in *E. rhusiopathiae*. We conclude that the down-regulation of the TCA cycle and the down-regulation of several proteins are associated with virulence in this organism.

Supporting Information

S1 Fig. Comparisons between various biological replicates. The difference was plotted versus the percentage of the proteins identified. Approximately 82.4% of proteins had cv differences less than 0.1, and more than 99.7% of the proteins had cv errors less than 0.5.

(PNG)

S2 Fig. Survival rate of mice in each group after infection.

(TIF)

S3 Fig. Antibody levels in serum of mice immunized with different type of vaccines.

(TIF)

S1 File. Full annotation of proteins identified in strains HX130709a and HX130709.

(XLS)

S1 Table. Differentially regulated genes identified by RNA-Seq (HX130709a/HX130709).

(DOCX)

Acknowledgments

This manuscript was modified by Ms. Elizabeth G. Wills.

Author Contributions

Conceived and designed the experiments: YFL PJ.

Performed the experiments: YTX YZ.

Analyzed the data: XWW JB.

Contributed reagents/materials/analysis tools: YTX.

Wrote the paper: YFL.

References

1. Wood RL. Erysipelas. Diseases of swine, 8th ed (Straw BE, D'Allaire S, Mengeling WL, et al), Iowa State University Press, Ames. 1999:419–30.
2. Bender JS, Shen HG, Irwin CK, Schwartz KJ, Opriessnig T. Characterization of Erysipelothrix species isolates from clinically affected pigs, environmental samples, and vaccine strains from six recent swine erysipelas outbreaks in the United States. Clinical and vaccine immunology: CVI. 2010; 17(10):1605–11. Epub 2010/08/20. doi: [10.1128/CVI.00206-10](https://doi.org/10.1128/CVI.00206-10) PMID: [20719987](https://pubmed.ncbi.nlm.nih.gov/20719987/); PubMed Central PMCID: PMC2952986.
3. Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. Journal of medical microbiology. 1999; 48(9):789–99. Epub 1999/09/11. PMID: [10482289](https://pubmed.ncbi.nlm.nih.gov/10482289/).
4. Shimoji Y. Pathogenicity of Erysipelothrix rhusiopathiae: virulence factors and protective immunity. Microbes and infection / Institut Pasteur. 2000; 2(8):965–72. Epub 2000/08/30. PMID: [10962280](https://pubmed.ncbi.nlm.nih.gov/10962280/).
5. Bender JS, Irwin CK, Shen H-G, Schwartz KJ, Opriessnig T. Erysipelothrix spp. genotypes, serotypes, and surface protective antigen types associated with abattoir condemnations. Journal of Veterinary Diagnostic Investigation. 2011; 23(1):139–42. WOS:000286953200025. PMID: [21217046](https://pubmed.ncbi.nlm.nih.gov/21217046/)
6. Eamens GJ, Forbes WA, Djordjevic SP. Characterisation of Erysipelothrix rhusiopathiae isolates from pigs associated with vaccine breakdowns. Veterinary microbiology. 2006; 115(4):329–38. Epub 2006/04/20. doi: [10.1016/j.vetmic.2006.02.015](https://doi.org/10.1016/j.vetmic.2006.02.015) PMID: [16621346](https://pubmed.ncbi.nlm.nih.gov/16621346/).
7. Imada Y, Takase A, Kikuma R, Iwamaru Y, Akachi S, Hayakawa Y. Serotyping of 800 strains of Erysipelothrix isolated from pigs affected with erysipelas and discrimination of attenuated live vaccine strain by genotyping. Journal of Clinical Microbiology. 2004; 42(5):2121–6. doi: [10.1128/Jcm.42.5.2121-2126.2004](https://doi.org/10.1128/Jcm.42.5.2121-2126.2004). ISI:000221424100039. PMID: [15131179](https://pubmed.ncbi.nlm.nih.gov/15131179/)
8. Ozawa M, Yamamoto K, Kojima A, Takagi M, Takahashi T. Etiological and Biological Characteristics of Erysipelothrix rhusiopathiae Isolated between 1994 and 2001 from Pigs with Swine Erysipelas in Japan. Journal of Veterinary Medical Science. 2009; 71(6):697–702. ISI:000267775600001. PMID: [19578275](https://pubmed.ncbi.nlm.nih.gov/19578275/)
9. Takahashi T, Nagamine N, Kijima M, Suzuki S, Takagi M, Tamura Y, et al. Serovars of Erysipelothrix strains isolated from pigs affected with erysipelas in Japan. Journal of Veterinary Medical Science. 1996; 58(6):587–9. WOS:A1996UU68500021. PMID: [8811634](https://pubmed.ncbi.nlm.nih.gov/8811634/)
10. Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Veterinary microbiology. 2010; 140(3–4):405–17. Epub 2009/09/08. doi: [10.1016/j.vetmic.2009.08.012](https://doi.org/10.1016/j.vetmic.2009.08.012) PMID: [19733019](https://pubmed.ncbi.nlm.nih.gov/19733019/).
11. Reboli AC, Farrar WE. Erysipelothrix rhusiopathiae: an occupational pathogen. Clinical microbiology reviews. 1989; 2(4):354–9. Epub 1989/10/01. PMID: [2680056](https://pubmed.ncbi.nlm.nih.gov/2680056/); PubMed Central PMCID: PMC358129.
12. Wang Q, Chang BJ, Mee BJ, Riley TV. Neuraminidase production by Erysipelothrix rhusiopathiae. Veterinary microbiology. 2005; 107(3–4):265–72. Epub 2005/05/03. doi: [10.1016/j.vetmic.2005.01.022](https://doi.org/10.1016/j.vetmic.2005.01.022) PMID: [15863286](https://pubmed.ncbi.nlm.nih.gov/15863286/).
13. Shimoji Y, Yokomizo Y, Sekizaki T, Mori Y, Kubo M. Presence of a capsule in Erysipelothrix rhusiopathiae and its relationship to virulence for mice. Infection and immunity. 1994; 62(7):2806–10. Epub 1994/07/01. PMID: [8005671](https://pubmed.ncbi.nlm.nih.gov/8005671/); PubMed Central PMCID: PMC302885.
14. Shimoji Y, Ogawa Y, Osaki M, Kabeya H, Maruyama S, Mikami T, et al. Adhesive surface proteins of Erysipelothrix rhusiopathiae bind to polystyrene, fibronectin, and type I and IV collagens. Journal of bacteriology. 2003; 185(9):2739–48. Epub 2003/04/18. PMID: [12700253](https://pubmed.ncbi.nlm.nih.gov/12700253/); PubMed Central PMCID: PMC154401.
15. Galan JE, Timoney JF. Cloning and expression in Escherichia coli of a protective antigen of Erysipelothrix rhusiopathiae. Infection and immunity. 1990; 58(9):3116–21. Epub 1990/09/01. PMID: [1696940](https://pubmed.ncbi.nlm.nih.gov/1696940/); PubMed Central PMCID: PMC313619.

16. Zou Y, Zhu X, Muhammad HM, Jiang P, Li Y. Characterization of *Erysipelothrix rhusiopathiae* strains isolated from acute swine erysipelas outbreaks in Eastern China. *The Journal of veterinary medical science / the Japanese Society of Veterinary Science*. 2015; 77(6):653–60. Epub 2015/02/05. doi: [10.1292/jvms.14-0589](https://doi.org/10.1292/jvms.14-0589) PMID: [25649849](https://pubmed.ncbi.nlm.nih.gov/25649849/); PubMed Central PMCID: PMC4488401.
17. Yoder-Himes DR, Chain PS, Zhu Y, Wurtzel O, Rubin EM, Tiedje JM, et al. Mapping the *Burkholderia cenocepacia* niche response via high-throughput sequencing. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106(10):3976–81. Epub 2009/02/24. doi: [10.1073/pnas.0813403106](https://doi.org/10.1073/pnas.0813403106) PMID: [19234113](https://pubmed.ncbi.nlm.nih.gov/19234113/); PubMed Central PMCID: PMC2645912.
18. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nature methods*. 2008; 5(7):621–8. Epub 2008/06/03. doi: [10.1038/nmeth.1226](https://doi.org/10.1038/nmeth.1226) PMID: [18516045](https://pubmed.ncbi.nlm.nih.gov/18516045/).
19. Wang L, Feng Z, Wang X, Zhang X. DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. *Bioinformatics*. 2010; 26(1):136–8. Epub 2009/10/27. doi: [10.1093/bioinformatics/btp612](https://doi.org/10.1093/bioinformatics/btp612) PMID: [19855105](https://pubmed.ncbi.nlm.nih.gov/19855105/).
20. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8—a global view on proteins and their functional interactions in 630 organisms. *Nucleic acids research*. 2009; 37(Database issue):D412–6. Epub 2008/10/23. doi: [10.1093/nar/gkn760](https://doi.org/10.1093/nar/gkn760) PMID: [18940858](https://pubmed.ncbi.nlm.nih.gov/18940858/); PubMed Central PMCID: PMC2686466.
21. Gaigalat L, Schluter JP, Hartmann M, Mormann S, Tauch A, Puhler A, et al. The DeoR-type transcriptional regulator SugR acts as a repressor for genes encoding the phosphoenolpyruvate:sugar phosphotransferase system (PTS) in *Corynebacterium glutamicum*. *BMC molecular biology*. 2007; 8:104. Epub 2007/11/17. doi: [10.1186/1471-2199-8-104](https://doi.org/10.1186/1471-2199-8-104) PMID: [18005413](https://pubmed.ncbi.nlm.nih.gov/18005413/); PubMed Central PMCID: PMC2222622.
22. Shi F, Harada T, Ogawa Y, Ono H, Ohnishi-Kameyama M, Miyamoto T, et al. Capsular polysaccharide of *Erysipelothrix rhusiopathiae*, the causative agent of swine erysipelas, and its modification with phosphorylcholine. *Infection and immunity*. 2012; 80(11):3993–4003. Epub 2012/09/06. doi: [10.1128/IAI.00635-12](https://doi.org/10.1128/IAI.00635-12) PMID: [22949554](https://pubmed.ncbi.nlm.nih.gov/22949554/); PubMed Central PMCID: PMC3486058.
23. Kwok AH, Li Y, Jiang J, Jiang P, Leung FC. Complete genome assembly and characterization of an outbreak strain of the causative agent of swine erysipelas—*Erysipelothrix rhusiopathiae* SY1027. *BMC microbiology*. 2014; 14:176. Epub 2014/07/06. doi: [10.1186/1471-2180-14-176](https://doi.org/10.1186/1471-2180-14-176) PMID: [24993343](https://pubmed.ncbi.nlm.nih.gov/24993343/); PubMed Central PMCID: PMC4105556.
24. Shimoji Y, Asato H, Sekizaki T, Mori Y, Yokomizo Y. Hyaluronidase is not essential for the lethality of *Erysipelothrix rhusiopathiae* infection in mice. *The Journal of veterinary medical science / the Japanese Society of Veterinary Science*. 2002; 64(2):173–6. Epub 2002/03/27. PMID: [11913558](https://pubmed.ncbi.nlm.nih.gov/11913558/).
25. Borrathybay E, Gong FJ, Zhang L, Nazierbieke W. Role of Surface Protective Antigen A in the Pathogenesis of *Erysipelothrix rhusiopathiae* strain C43065. *Journal of microbiology and biotechnology*. 2014. Epub 2014/09/17. PMID: [25223326](https://pubmed.ncbi.nlm.nih.gov/25223326/).